JO3114B1 - مركبات بيريدازينون - Google Patents

مركبات بيريدازينون

Info

Publication number
JO3114B1
JO3114B1 JOP/2010/0038A JOP20100038A JO3114B1 JO 3114 B1 JO3114 B1 JO 3114B1 JO P20100038 A JOP20100038 A JO P20100038A JO 3114 B1 JO3114 B1 JO 3114B1
Authority
JO
Jordan
Prior art keywords
ring
substituent
substituted
compound
pyridazinone compounds
Prior art date
Application number
JOP/2010/0038A
Other languages
English (en)
Inventor
Kawada Akira
Taniguchi Takahiko
F Quinn John
Kunitomo Jun
Yoshikawa Masato
Fushimi Makoto
Kondo Mitsuyo
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of JO3114B1 publication Critical patent/JO3114B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يوفر الاختراع الحالي مركب الذي له تأثير على تثبيط PDE، والذي يكون مفيدا كدواء لمنع أو معالجة الفصام الذهني، إلخ. مركب (compound) من الصيغة (I): حيث: R1 يمثل بديل، R2 يمثل ذرة hydrogen، أو بديل، R3 يمثل ذرة hydrogen، أو بديل، الحلقة A تمثل حلقة aromatic التي يمكن أن تستبدل، و الحلقة B تمثل حلقة heteroaromatic لها 5 أعضاء التي يمكن أن تستبدل، أو ملح (salt) من ذلك.
JOP/2010/0038A 2009-02-05 2010-02-04 مركبات بيريدازينون JO3114B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20220709P 2009-02-05 2009-02-05
US21392709P 2009-07-30 2009-07-30

Publications (1)

Publication Number Publication Date
JO3114B1 true JO3114B1 (ar) 2017-09-20

Family

ID=42398214

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0038A JO3114B1 (ar) 2009-02-05 2010-02-04 مركبات بيريدازينون

Country Status (38)

Country Link
US (7) US8354411B2 (ar)
EP (2) EP2393360B1 (ar)
JP (1) JP5659166B2 (ar)
KR (1) KR101730665B1 (ar)
CN (1) CN102365020B (ar)
AR (1) AR075238A1 (ar)
AU (1) AU2010211050B2 (ar)
BR (1) BRPI1008498B8 (ar)
CA (1) CA2751565C (ar)
CO (1) CO6410258A2 (ar)
CR (1) CR20110440A (ar)
DK (1) DK2393360T3 (ar)
DO (1) DOP2011000254A (ar)
EA (1) EA020690B1 (ar)
EC (1) ECSP11011305A (ar)
ES (1) ES2561181T3 (ar)
GE (1) GEP20146004B (ar)
HK (1) HK1164642A1 (ar)
HR (1) HRP20160065T1 (ar)
HU (1) HUE027478T2 (ar)
IL (1) IL214137A (ar)
JO (1) JO3114B1 (ar)
MA (1) MA33072B1 (ar)
ME (1) ME02337B (ar)
MX (1) MX2011008305A (ar)
MY (1) MY170610A (ar)
NZ (1) NZ594851A (ar)
PE (1) PE20110991A1 (ar)
PL (1) PL2393360T3 (ar)
RS (1) RS54504B1 (ar)
SG (1) SG173175A1 (ar)
SI (1) SI2393360T1 (ar)
SM (1) SMT201600008B (ar)
TN (1) TN2011000362A1 (ar)
TW (1) TWI457333B (ar)
UY (1) UY32417A (ar)
WO (1) WO2010090737A1 (ar)
ZA (1) ZA201106074B (ar)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054791A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
CN102365020B (zh) 2009-02-05 2014-07-30 武田药品工业株式会社 哒嗪酮化合物
MX341446B (es) 2010-06-24 2016-08-19 Takeda Pharmaceuticals Co Compuestos heterociclicos fusionados como inhibidores de fosfodiesterasas (pdes).
US20130116231A1 (en) * 2010-07-12 2013-05-09 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
WO2012018059A1 (ja) 2010-08-04 2012-02-09 武田薬品工業株式会社 複素環化合物
EP2601192B1 (en) 2010-08-04 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
WO2012018058A1 (ja) 2010-08-04 2012-02-09 武田薬品工業株式会社 縮合複素環化合物
EP2604597B1 (en) * 2010-08-10 2017-01-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a
JP2013234123A (ja) * 2010-09-03 2013-11-21 Taisho Pharmaceutical Co Ltd ３−ピラゾリル−２−ピリドン誘導体
WO2012112946A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
JP5973990B2 (ja) 2011-03-16 2016-08-23 武田薬品工業株式会社 縮合複素環化合物
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
CA2846122C (en) * 2011-08-22 2019-06-11 Takeda Pharmaceutical Company Limited Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (pde10a) in mammals
US9212147B2 (en) 2011-11-15 2015-12-15 Takeda Pharmaceutical Company Limited Dihydroxy aromatic heterocyclic compound
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
AR094717A1 (es) * 2013-02-21 2015-08-19 Takeda Pharmaceuticals Co Método de producción de compuestos de piridazinona
US9464076B2 (en) 2013-03-15 2016-10-11 Daiichi Sankyo Company, Limited Benzothiophene derivative
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
ES2821394T3 (es) 2013-09-12 2021-04-26 Alios Biopharma Inc Compuestos de 7,8-dihidro-3H-pirazino[1,2-b]piridazin-3,5(6H)-diona y usos de los mismos
EP3030549B8 (en) 2013-09-12 2019-04-10 Janssen BioPharma, Inc. Pyridazinone compounds and uses thereof
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
ES2544869B2 (es) * 2014-03-04 2016-01-18 Universidade De Vigo Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa
EP3120871B1 (en) * 2014-03-18 2023-06-28 Takeda Pharmaceutical Company Limited Solid dispersion
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
MX2017011655A (es) 2015-03-11 2018-04-30 Alios Biopharma Inc Compuestos de aza-piridona y usos de estos.
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
MX2018007844A (es) 2015-12-22 2019-01-21 Jiangsu Hengrui Medicine Co Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo.
US10736894B2 (en) 2018-02-15 2020-08-11 Ovid Therapeutics Inc. Methods of treating developmental syndromes with PDE10A inhibitors
CN108498868B (zh) * 2018-04-03 2020-09-15 北京大学口腔医学院 具有细胞外基质电学拓扑特征的带电复合膜及其制备方法
CN110407806B (zh) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
WO2019241787A1 (en) * 2018-06-15 2019-12-19 The Regents Of The University Of Colorado A Body Corporate Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use
JP2022501335A (ja) * 2018-09-28 2022-01-06 武田薬品工業株式会社 自閉症スペクトラム障害を治療または予防するためのバリポデクト（Ｂａｌｉｐｏｄｅｃｔ）
MX2019008440A (es) 2019-07-15 2021-01-18 Dva Farma Mexicana S A De C V Composiciones de recubrimientos en pelicula para tabletas con brillantez incrementada, procedimiento de preparacion y aplicacion.
GB202002926D0 (en) 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0011693A1 (de) * 1978-10-03 1980-06-11 Ciba-Geigy Ag Neue N-(trifluormethansulfonylaminophenyl)-substituierte N-Heterocyclen, ihre Herstellung, sie enthaltende Mittel und ihre Verwendung zur Beeinflussung des Pflanzenwachstums
FR2648135B1 (fr) 1989-06-07 1991-09-27 Pf Medicament Derives de phenyl-1-dihydro-1,4 amino-3 oxo-4 pyridazines, leur preparation et leur application en therapeutique
GB9506382D0 (en) 1995-03-29 1995-05-17 Boots Co Plc Pharmaceutical compositions
CN1263746C (zh) 1998-08-14 2006-07-12 日本农药株式会社 哒嗪酮衍生物
US20070060606A1 (en) 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
WO2002022603A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
WO2005120514A1 (en) 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
CN101098866A (zh) 2005-01-07 2008-01-02 辉瑞产品公司 杂芳族喹啉化合物及其作为pde10抑制剂的用途
WO2006095666A1 (ja) 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン－４－イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP2009541481A (ja) 2006-06-26 2009-11-26 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害剤としての三環式ヘテロアリール化合物
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
AR074343A1 (es) 2008-11-14 2011-01-12 Amgen Inc Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
MX2011005449A (es) * 2008-12-04 2011-06-09 Hoffmann La Roche Derivados de piridazinona.
CN102365020B (zh) * 2009-02-05 2014-07-30 武田药品工业株式会社 哒嗪酮化合物
US9187455B2 (en) 2009-02-23 2015-11-17 Hoffmann-La Roche Inc. Substituted pyridazines as PDE10A inhibitors
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
WO2012018058A1 (ja) * 2010-08-04 2012-02-09 武田薬品工業株式会社 縮合複素環化合物
EP2604597B1 (en) * 2010-08-10 2017-01-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a

Also Published As

Publication number Publication date
KR20110120931A (ko) 2011-11-04
US20120277430A1 (en) 2012-11-01
CR20110440A (es) 2012-02-13
MX2011008305A (es) 2012-08-15
US9550756B2 (en) 2017-01-24
US20100197651A1 (en) 2010-08-05
AU2010211050B2 (en) 2016-05-12
BRPI1008498B8 (pt) 2021-05-25
WO2010090737A1 (en) 2010-08-12
UY32417A (es) 2010-08-31
US8916566B2 (en) 2014-12-23
US8778944B2 (en) 2014-07-15
ES2561181T3 (es) 2016-02-24
PL2393360T3 (pl) 2016-04-29
TWI457333B (zh) 2014-10-21
IL214137A (en) 2015-07-30
NZ594851A (en) 2013-10-25
ZA201106074B (en) 2012-10-31
SG173175A1 (en) 2011-09-29
GEP20146004B (en) 2014-01-10
DOP2011000254A (es) 2011-09-30
IL214137A0 (en) 2011-08-31
US20120277204A1 (en) 2012-11-01
MA33072B1 (ar) 2012-02-01
BRPI1008498A2 (pt) 2015-08-25
TW201036958A (en) 2010-10-16
HK1164642A1 (zh) 2012-09-28
SI2393360T1 (sl) 2016-02-29
EP2393360A1 (en) 2011-12-14
US8354411B2 (en) 2013-01-15
AR075238A1 (es) 2011-03-16
HRP20160065T1 (hr) 2016-02-12
US8435995B2 (en) 2013-05-07
JP5659166B2 (ja) 2015-01-28
EP2393360A4 (en) 2012-08-15
TN2011000362A1 (en) 2013-03-27
US20170114044A1 (en) 2017-04-27
BRPI1008498B1 (pt) 2020-02-11
US8513251B2 (en) 2013-08-20
CA2751565C (en) 2017-05-16
ECSP11011305A (es) 2011-11-30
ME02337B (me) 2016-06-20
CA2751565A1 (en) 2010-08-12
EA201171004A1 (ru) 2012-03-30
EA020690B1 (ru) 2015-01-30
MY170610A (en) 2019-08-20
US20120028951A1 (en) 2012-02-02
SMT201600008B (it) 2016-02-25
EP3006031A1 (en) 2016-04-13
HUE027478T2 (en) 2016-09-28
JP2012516890A (ja) 2012-07-26
PE20110991A1 (es) 2012-02-06
AU2010211050A2 (en) 2011-10-06
DK2393360T3 (en) 2016-02-01
CO6410258A2 (es) 2012-03-30
US20150099757A1 (en) 2015-04-09
AU2010211050A1 (en) 2011-09-08
RS54504B1 (en) 2016-06-30
CN102365020B (zh) 2014-07-30
KR101730665B1 (ko) 2017-04-26
CN102365020A (zh) 2012-02-29
EP2393360B1 (en) 2015-11-04
US20120277431A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
JO3114B1 (ar) مركبات بيريدازينون
MX2012015098A (es) Compuestos heterociclicos fusionados como inhibidores de fosfodiesterasas (pdes).
MX2010009736A (es) Compuesto heterociclico.
JO2732B1 (ar) المركبـــات العضويــة
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
MX361020B (es) Procesos para preparar compuestos heterociclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo [3,2,1]octano-2-carboxam ida y sales de la misma.
MY152972A (en) Azabicyclo compound and salt thereof
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
TN2009000012A1 (en) Amino-piperidine derivatives as cetp inhibitors
MY169179A (en) Novel piperidine compound or salt thereof
TNSN07348A1 (en) Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor
IN2012DN00770A (ar)
TNSN08494A1 (en) Spirocyclic nitriles as protease inhibitors
MX353190B (es) Derivados de isoquinolina y naftiridina.
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
IN2012DN00768A (ar)
EP2602254A4 (en) HETEROCYCLIC COMPOUND
NZ611169A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
MX2009004982A (es) Derivados heterociclicos como inhibidores cetp.
MX2009005249A (es) Compuestos organicos.
MY164789A (en) Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine
NZ595890A (en) Pyrazole compound
UA106741C2 (uk) Піридазинони
WO2010141550A3 (en) 11beta-hydroxysteroid dehydrogenase type 1 (11-beta hsd1) inhibitors
TH162570B (th) สารประกอบไพริดาซิโนน